CSPC Pharma Gains Approval for New Cancer Drug Trials

TipRanksDec 30 04:38 ET

CSPC PHARMA (01093.HK) spent HKD 29.5844 million to repurchase 6.2 million shares on December 30.

On December 30, 2023, CSPC PHARMA (01093.HK) announced that it spent 29.5844 million Hong Kong dollars to repurchase 6.2 million shares at a repurchase price of 4.74-4.81 Hong Kong dollars per share.

Gelonghui FinanceDec 30 04:37 ET

CSPC PHARMA (01093.HK): Leuprolide Acetate Sustained-Release Injection (SYH9016) has received clinical trial approval.

On December 30, Gelonghui reported that CSPC PHARMA (01093.HK) announced that the GnRH receptor agonist, Leuprolide Acetate Slow Release Injection (SYH9016), developed by the group, has been approved by the National Medical Products Administration of China for clinical trials in China. This product is the first modified Leuprolide product approved for clinical trials domestically, utilizing the group's long-acting delivery technology platform, based on excipients with good biocompatibility, forming a gel reservoir after subcutaneous injection, which enables long-acting drug delivery. This product is administered once a month, compared to the already marketed microsphere product of Leuprolide.

Gelonghui FinanceDec 30 04:27 ET

Express News | CSPC Pharmaceutical - Clinical Trial Approval Granted by Nmpa of China

ReutersDec 30 04:25 ET

Express News | Voluntary Announcement - Leuprorelin Extended-Release Injection (Syh9016) Obtains Clinical Trial Approval

ReutersDec 30 04:25 ET

CSPC PHARMA (01093.HK) spent HK$29.5996 million to repurchase 6.2 million shares on December 27.

On December 27, Gelonghui reported that CSPC PHARMA (01093.HK) announced the repurchase of 6.2 million shares at a cost of HKD 29.5996 million on December 27, 2024, with a repurchase price of HKD 4.75-4.8 per share.

Gelonghui FinanceDec 27 04:32 ET